In this project we propose to investigate and validate the predictive value of a mRNA-expresession profile for our autologous dendritic cell immunotherapy. We will correlate the baseline tumor mRNA expression profile with CRP-levels measured in the blood of patients as we have documented a strong correlation between baseline CRP-levels and the outcome of melanoma patients treated with ipilimumab in our institutional practice. Melanoma tissues will be obtained from patients participating in two prospective clinical trials conducted by our research group investigating the TriMixDX-MEL cellular immunotherapy either as a single agent in a randomized phase II trail in the adjuvant setting and in combination with ipilimumab in a phase II trial for patients with measurable disease.